Board Member
Corcept Therapeutics Inc (CORT)Equibles does not estimate personal net worth.
Get an email with a short summary when Corcept Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get CORT alertsJoseph K. Belanoff is recorded as Board Member and CEO at Corcept Therapeutics Inc (CORT). The newest filing on record that lists Joseph K. Belanoff as Board Member and CEO at Corcept Therapeutics Inc (CORT) is dated April 17, 2026. The proxy statement of Corcept Therapeutics Inc reports total compensation of $15,303,551 for Joseph K. Belanoff in fiscal 2025, including a base salary of $1,182,333. Disclosed compensation is on record for 9 fiscal years. Joseph K. Belanoff has spoken on 20 earnings calls across 1 company, most recently for Corcept Therapeutics Inc on April 30, 2026. Corcept Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Corcept Therapeutics Inc includes James N. Wilson (Chairman and Board Member), Atabak Mokari (CFO), Joshua M. Murray (CFO, Head of Investor Relations and Board Member) and 7 others.
“Since CORCEP's inception, we have explored the potential of cortisol modulation to treat patients with serious diseases. That potential is vast. We have made important advances.”
“After many important years building this point, the next era at Corsept is about to arrive. As we have always known, cortisol enters all organs of the body, and modulating its effects has the potential to be useful in many diseases.”
“This has been an extremely active period at Corcept. Our commercial business continues to be very strong and we are making progress in all of our clinical development programs.”
“As the awareness and diagnosis of Cushing's syndrome increase, we are simultaneously working to advance our proprietary selective cortisol modulator, relacorilant.”
“And thank you, everyone, for joining us this afternoon. Atabak highlighted our strong commercial performance and the revenue guidance we have set for 2024. A few weeks ago, I had the opportunity to meet with our endocrinology team at our National Field Meeting.”
Start not stated–present
Last confirmed April 17, 2026
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $1,182,333 | $15,303,551 |
| 2024 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $1,140,533 | $9,890,081 |
| 2023 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $1,083,333 | $9,337,734 |
| 2022 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $895,833 | $7,352,757 |
| 2021 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $843,750 | $10,984,638 |
| 2020 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $769,567 | $5,762,102 |
| 2019 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $707,525 | $4,958,970 |
| 2018 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $679,792 | $6,314,617 |
| 2017 | Corcept Therapeutics Inc (CORT) | M.D., Chief Executive Officer and President | $647,333 | $4,271,452 |
